Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2024; 12(19): 3890-3897
Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3890
Efficacy of fexuprazan compared with rebamipide in Korean patients with gastritis: A matching-adjusted indirect comparison
Gwang Ha Kim, Hang Lak Lee
Gwang Ha Kim, Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea
Hang Lak Lee, Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, South Korea
Author contributions: Kim GH conceived and designed the study; Kim GH and Lee HL collected data and performed data analysis; Kim GH and Lee HL wrote the draft of this manuscript; Kim GH edited the manuscript.
Conflict-of-interest statement: All authors declare no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gwang Ha Kim, MD, PhD, Professor, Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, South Korea. doc0224@pusan.ac.kr
Received: March 18, 2024
Revised: May 3, 2024
Accepted: May 22, 2024
Published online: July 6, 2024
Processing time: 103 Days and 4.8 Hours
Core Tip

Core Tip: In a matching-adjusted indirect comparison, the effectiveness of fexuprazan, a novel potassium-competitive acid blocker, was compared with that of rebamipide, one of the most commonly used mucoprotective agents for acute and chronic gastritis in a real-world setting in South Korea. We conclude that a two-week fexuprazan treatment is superior to a two-week rebamipide treatment and similar to a four-week rebamipide treatment for patients with gastritis.